4144413
Last Update Posted: 2024-08-28
Recruiting has ended
All Genders accepted | 18 Years + |
350 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis® (1mg/mL ciclosporin) eye drops administered once daily
Eligibility
Relevant conditions:
Dry Eye Disease With Severe Keratitis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov